Skip to main content Skip to main navigation menu Skip to site footer

Chronic dialysis patient with severe secondary hyperparathyroidism undergoing parathyroidectomy in Indonesia: a case series

  • Adaninggar Nariswari ,
  • Kevin Tandarto ,
  • Aditiawardana ,


Link of Video Abstract:

Parathyroidectomy is a method of treating secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD), which has been largely abandoned in developed countries due to the existence of calcimimetic drugs which are reported to be effective in treating secondary hyperparathyroidism in this population. However, in developing countries like Indonesia, the availability of Calcimimetic drugs is still rare and expensive, so that parathyroidectomy can be an option. The study aimed to present four case reports of chronic HD patients with SHPT accompanied by clinical symptoms. As far as our knowledge goes, this is the first case series reported from Indonesia.

Case Presentation: This research is a multicenter case series study. All patients had undergone dialysis for five years and complained of body aches. All calcium levels were within the normal range, while three patients had hyperphosphatemia and one patient had normal phosphate levels. All patients had iPTH levels >1000 pg/ml in the last six months. Before the surgery, all patients had received long-term phosphate-binding drugs, including calcium-based and non-calcium-based drugs and vitamin D3 agonists. All patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue in the right antebrachial regions, except for the second patient who received the transplant in the left antebrachial region due to an AV fistula in the right arm.

Conclusion: In dialysis patients, especially in developing countries, approximately 10.7% of them experience SHPT with PTH levels >1,000 pg/mL, and one study in Indonesia showed that around 35% of patients undergoing chronic hemodialysis had PTH levels >200 pg/ml, making parathyroidectomy a highly possible option considering that medications such as cinacalcet are more expensive and not widely available.


  1. Bureo JC, Arévalo JC, Antón J, Adrados G, Jiménez Morales JL, Robles NR. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol Nutr. 2015;62(7):300–305.
  2. Ramos AM, Albalate M, Vázquez S, Caramelo C, Egido J, Ortiz A. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int Suppl. 2008;(111):S88–S93.
  3. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913–921.
  4. van der Plas WY, Noltes ME, van Ginhoven TM, Kruijff S. Secondary and Tertiary Hyperparathyroidism: A Narrative Review. Scand J Surg. 2020;109(4):271-278.
  5. Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;88(2):350-359.
  6. Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clinical Journal of the American Society of Nephrology. 2018;13(6):952-961.
  7. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013;98(12):4834–4844.
  8. Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, et al. Effect of etecalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017;317(2):146–155.
  9. Park H, Rascati KL, Lawson KA, Barner JC, Richards KM, Malone DC. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase. J Manag Care Spec Pharm. 2014;20(8):862–876.
  10. Konstantinidis I, Nadkarni G, Divino CM, Lapsia V. Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease. Clin Kidney J. 2013;6(3):277–282.
  11. Zhang Y, Lu Y, Feng S, Zhan Z, Shen H. Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Renal Fail. 2019;41(1):921–929.
  12. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423–1429.
  13. Moe S, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium phosphorus product. Am J Nephrol. 2003;23(6):369–379.
  14. St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C,et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol. 2009;4(2):354–360.
  15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59.
  16. Oliveira RB, Silva EN, Charpinel DM, Gueiros JE, Neves CL, Sampaio EA, et al. Secondary hyperparathyroidism status in Brazil: Brazilian census of parathyroidectomy. J Bras Nefrol. 2011;33(4):457-462.
  17. Santoso D, Yogiantoro M, Tomino Y. Osteodystrophy in Indonesian haemodialysis patients. Nephrology (Carlton). 2003;8(5):261-265.
  18. Steinl GK, Kuo JH. Surgical Management of Secondary Hyperparathyroidism. Kidney Int Rep. 2020;6(2):254-264.
  19. Fotheringham J, Balasubramanian SP, Harrison B, Wilkie M. Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival: a single-centre study in a stage 5 chronic kidney disease population. Nephron Clin Pract. 2011;119(2):c113-c120.
  20. Zhu M, Zhang Z, Lin F, Miao J, Wang P, Zhang C, et al. Therapeutic experience of severe and recurrent secondary hyperparathyroidism in a patient on hemodialysis for 18 years: A case report. Medicine (Baltimore). 2018;97(20):e10816.
  21. Sari R, Yabanoglu H, Hargura AS, Kus M, Arer IM. Outcomes of Total Parathyroidectomy with Autotransplantation versus Subtotal Parathyroidectomy Techniques for Secondary Hyperparathyroidism in Chronic Renal Failure. J Coll Physicians Surg Pak. 2020;30(1):18-22.
  22. Yuan Q, Liao Y, Zhou R, Liu J, Tang J, Wu G. Subtotal para- thyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: an updated systematic review and meta-analysis. Langenbecks Arch Surg. 2019;404(6):669–679.
  23. Nascimento Junior CP, Arap SS, Custodio MR, et al. Parathyroid hormone levels after parathyroidectomy for secondary hyperparathyroidism. Rev Assoc Med Bras (1992). 2021;67(2):230-234.
  24. Pepe J, Colangelo L, Biamonte F, et al. Diagnosis and management of hypocalcemia. Endocrine. 2020;69(3):485-495.
  25. Florescu MC, Islam KM, Plumb TJ, Smith-Shull S, Nieman J, Mandalapu P. Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients. Int J Nephrol Renovasc Dis. 2014;7:183–190.
  26. Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clinical Journal of the American Society of Nephrology. 2018;13(6):952-961.
  27. Stack BC, Bimston DN, Bodenner DL, Brett EM, Dralle H, Orloff LA, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: Postoperative Hypoparathyroidism Definitions And Management. Endocr Pract 2015;21)(6):674–685.
  28. Jain N, Reilly RF. Hungry bone syndrome. Curr Opin Nephrol Hypertens. 2017;26(4):250–255.
  29. Goh BL, Yudisthra MG, Hisham AN. Alkaline phosphatase predicts calcium requirements after total parathyroidectomy in patients receiving dialysis. Br J Surg. 2010;97(2):185–188.
  30. Wang M, Chen B, Zou X, Wei T, Gong R, Zhu J, et al. A nomogram to predict hungry bone syndrome after parathyroidectomy in patients with secondary hyperparathyroidism. J Surg Res. 2020;255:33–41.
  31. Chou FF, Chen JB. Severe hypocalcemia after total parathyroidectomy plus autotransplantation for secondary hyperparathyroidism-risk factors and clinical algorithm. Intech Open. 2020;1(1):1-13
  32. Cozzolino M, Gallieni M, Corsi C, Bastagli A, Brancaccio D. Management of calcium refilling post-parathyroidectomy in end-stage renal disease. Journal of Nephrology. 2004;17(1):3-8.
  33. Loke SC, Kanesvaran R, Yahya R, Fisal L, Wong TW, Loong YY. Efficacy of an intravenous calcium gluconate infusion in controlling serum calcium after parathyroidectomy for secondary hyperparathyroidism. Ann Acad Med Singap. 2009;38(12):1074-1080.
  34. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201.
  35. Thadhani RI, Rosen S, Ofsthun NJ, Usvyat LA, Dalrymple LS, Maddux FW, et al. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2020;15(3):384-391.
  36. Rauscher S, Lafrance JP, Pichette V, Bell RZ, Desforges K, Lepage L, et al. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients. Int Urol Nephrol. 2017;49(2):325–328.
  37. Koc H, Hoser H, Akdag Y, Kendir C, Ersoy FF. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: An observational study. Int Urol Nephrol. 2019;51(7):1261–1270.
  38. Torregrosa JV, Ramos AM. Use of biphosphonates in chronic kidney disease. Nefrologia 2010;30(3):288-296.
  39. Vouri SM, Blaszczyk AT. Bisphosphonate use in patients undergoing dialysis. Consult Pharm. 2013;28(11):738-741.
  40. Tominaga Y, Matsuoka S, Uno N, Sato T. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial. 2008;12(Suppl 1):S21-S26.
  41. Kakani E, Sloan D, Sawaya BP, El-Husseini A, Malluche HH, Rao M. Long-term outcomes and management considerations after parathyroidectomy in the dialysis patient. Semin Dial. 2019;32(6):541-52.
  42. Kievit AJ, Tinnemans JG, Idu MM, Groothoff JW, Surachno S, Aronson DC. Outcome of total parathyroidectomy and autotransplantation as treatment of secondary and tertiary hyperparathyroidism in children and adults. World J Surg. 2010;34(5):993–1000.
  43. Schneider R, Ramaswamy A, Slater EP, Bartsch DK, Schlosser K. Cryopreservation of parathyroid tissue after parathyroid surgery for renal hyperparathyroidism: does it really make sense? World J Surg. 2012;36(11):2598-604..
  44. Chow TL, Chan TT, Ho YW, Lam SH. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg. 2007;142(7):644–648.
  45. Chutia H, Ruram AA, Bhattacharyya H, Boruah P, Nath C. Association of secondary hyperparathyroidism with hemoglobin level in patients with chronic kidney disease. J Lab Physicians. 2013;5(1):51–54.
  46. Mandolfo S, Malberti F, Farina M, Villa G, Scanziani R, Surian M, et al. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure. Nephrol Dial Transplant. 1998;13(10):2708-2709.
  47. Simeoni M, Perna AF, Fuiano G. Secondary Hyperparathyroidism and Hypertension: An Intriguing Couple. J Clin Med. 2020;9(3):629.
  48. Brown SJ, Ruppe MD, Tabatabai LS. The Parathyroid Gland and Heart Disease. Methodist Debakey Cardiovasc J. 2017;13(2):49-54.
  49. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol. 2007;292(4):F1215-F1218.
  50. Sofronie AC, Kooij I, Bursot C, Santagati G, Coindre JP, Piccoli GB. Full normalization of severe hypertension after parathryoidectomy - a case report and systematic review. BMC Nephrol. 2018;19(1):112.
  51. Worung IM, Lestari AAW, Kandarini Y, Wande IN, Wirawati IAP, Mahartini NN. Correlation between serum levels of Fibroblast Growth Factor-23 (FGF-23) and parathyroid hormone levels in predialysis Chronic Kidney Disease (CKD) patients at Sanglah General Hospital, Bali, Indonesia. Bali Medical Journal. 2021;10(2):830-834.
  52. Kusumawindani D, Mudjanarko SW, Novida H. Management of hypocalcemia in a person with hungry bone syndrome post parathyroidectomy due to parathyroid carcinoma: a case report. Bali Medical Journal. 2023;12(1):991-995.
  53. Setiawan FD, Novida H. Recurrent seizures as manifestation of hypoparathyroidism-related hypocalcemia in a patient with post-subtotal thyroidectomy. Bali Medical Journal. 2022;11(3):1780-1783.

How to Cite

Nariswari, A., Tandarto, K. ., & Aditiawardana. (2023). Chronic dialysis patient with severe secondary hyperparathyroidism undergoing parathyroidectomy in Indonesia: a case series. Bali Medical Journal, 12(2), 2153–2159.




Search Panel